Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
08/2003
08/27/2003EP1337258A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof
08/27/2003EP1337257A1 Use of neuropeptide-y antagonists in treatment of alcoholism
08/27/2003EP1337255A2 Use of p38 inhibitors for the treatment of inflammation-enhanced cough
08/27/2003EP1337253A1 Novel compounds
08/27/2003EP1337251A1 Monocyclic or bicyclic carbocycles and heterocycles as factor xa inhibitors
08/27/2003EP1337247A1 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
08/27/2003EP1337234A1 Use of 2-oxothiazolidine 4-carboxylic acid derivatives as agents promoting skin peeling
08/27/2003EP1267834A4 Cationic liposomes
08/27/2003EP1189902B1 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist
08/27/2003EP1140944B1 Epothilone derivatives and their use as antitumor agents
08/27/2003EP1140938B1 High affinity inhibitors for target validation and uses thereof
08/27/2003EP1140889B1 Compounds and methods for modulation of estrogen receptors
08/27/2003EP1095039B1 New pharmaceutically active compounds
08/27/2003EP1061951B1 Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin
08/27/2003EP0981515B1 Piperidine derivatives as neurotransmitter re-uptake inhibitors
08/27/2003EP0942740B1 Combination therapy using a tnf binding protein for treating tnf-mediated diseases
08/27/2003EP0901469B1 Arylalkylpiperazine compounds as antioxidants
08/27/2003EP0891363B1 Heterocyclic compounds and their preparation and use
08/27/2003EP0862552B1 Succinimide and maleimide cytokine inhibitors
08/27/2003EP0815084B1 Lactam-containing hydroxamic acid derivatives, their preparation and their use as inhibitors of matrix metalloprotease
08/27/2003CN1439022A Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof
08/27/2003CN1439018A 9alpha-chloro-6alpha-fluoro-17alpha-hydroxy-16-methyl-17-beta-methoxy carbonyl-androst-1, 4-dienes esterified in position 17 alpha by a cyclic acyl group
08/27/2003CN1439012A 2-zminoalkyl-thieno [2,3-D] pyrimidines
08/27/2003CN1439011A 5-aminoalkyl-pyrazolo [4,3-d] pyrimidines with phosphodiesterase v-inhibiting effect
08/27/2003CN1439010A Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents
08/27/2003CN1439009A Imidazo pyrimidine derivatives and triazolopyrimidine derivatives
08/27/2003CN1439008A 1-(heteroaryl-henyl)-condensed pyrazol derivatives as factor XA inhibitors
08/27/2003CN1439006A Novel compounds possessing antibacterial, antifungal or antitumor activity
08/27/2003CN1439005A Pyrrole substituted 2-indolinone protein kinase inhibitors
08/27/2003CN1439004A Indole derivatives useful for treatment of CNS-disorders
08/27/2003CN1439003A Arylmethy lamine derivatives for use as tryptase inhibitors
08/27/2003CN1439001A Tetrahydropyridino or piperidino hetlrocyclic derivatives
08/27/2003CN1438999A Serine protease inhibitors
08/27/2003CN1438998A Quinolinyl and benzothiazolyc PPAR-gamma modulators
08/27/2003CN1438997A Inhibitors of 11-beta-hydroxy steroid dehydrogenase typeÔàá"
08/27/2003CN1438996A Bicyclic cyclohexylamines and their use NMDA receptor antogonists
08/27/2003CN1438994A Polymorphic forms/hydrates of N-[4-(3-chloro-4-fluoro-phenylamino)-7- (3-morpholin-4-ylpropoxy)-quinazolin-6-Yl] acrylamide dihydrochloride
08/27/2003CN1438991A Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
08/27/2003CN1438895A Peptide composition
08/27/2003CN1438890A 腺苷受体调制剂 Adenosine receptor modulators
08/27/2003CN1438885A Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators
08/27/2003CN1438883A Beta Secretase inhibitors
08/27/2003CN1438882A Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
08/27/2003CN1438880A Method for preparing a composition
08/27/2003CN1438220A 1-(1,2-disubstituted piperidyl)-4-substituted diethylenediamine derivative
08/27/2003CN1438024A Medicine for regulating integral balance of human body
08/27/2003CN1438022A Cell-regeneration medicine of resisting senility of human body
08/27/2003CN1437968A Heat-clearing and stagnation-dissipating particle medicine and preparation method
08/27/2003CN1119421C Recombinant fusion proteins to growth hormone and serum albumin
08/27/2003CN1119346C Benzothiadiaxoles and derivatives
08/27/2003CN1119345C Benzo (5,6) cycloheptapyridine compounds use furl as farnesyl protein transferase inhibitors
08/27/2003CN1119344C Heterocyclic substed, pyrrolidine amide derivatives
08/27/2003CN1119334C Substsituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of disease charaterized by abnomal cell proliferation
08/27/2003CN1119328C Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists
08/27/2003CN1119313C Inhibition of matrix metallo proteases by 2-(omega-aroylalkyc)-4-biaryl-oxobutyric acids
08/27/2003CN1119165C Health-care drink of nourishing spleen and kidney
08/27/2003CN1119148C Use of alpha 1L agonists in treatment of in continence
08/27/2003CN1119147C Kappa-opiate agonists for inflammatory bowel disorders
08/26/2003US6610890 Treatment and/or prevention of diabetic complications; such as 3,3',4,4',5,5'-hexabromo-2,2'-dihydroxy-oxydiphenyl
08/26/2003US6610842 Removing hydroxyl protecting group from compound of given formula and treating with another compound; wide range of diagnostic and therapeutic uses
08/26/2003US6610839 Promoter for telomerase reverse transcriptase
08/26/2003US6610834 Human IgM antibodies to chemokine receptors
08/26/2003US6610829 Human extracellular matrix-1
08/26/2003US6610824 Amylin agonist peptides and uses therefor
08/26/2003US6610821 Cyclic peptide of given amino acid sequence; can use to improve drug delivery process, inhibit angiogenesis, increase vasopermeability; treatment of autoimmune and inflammatory diseases
08/26/2003US6610820 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
08/26/2003US6610746 Treating non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts and hyperglycemia; kits
08/26/2003US6610745 Use of 2-hydroxy-4-trifluoromethyl-benzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-KS
08/26/2003US6610743 Bicyclic metabotropic glutamate receptor ligands
08/26/2003US6610742 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists
08/26/2003US6610739 Amide and ester derivatives
08/26/2003US6610737 Non-psychotropic cannabinoids
08/26/2003US6610734 Heterocyclic sulfonamide inhibitors of beta amyloid production
08/26/2003US6610730 Viricides; protease inbhibitor
08/26/2003US6610727 Antitumor agents
08/26/2003US6610725 Fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof
08/26/2003US6610724 3-Aminopyrazole inhibitors of cyclin dependent kinases
08/26/2003US6610723 Imidazole derivatives
08/26/2003US6610719 Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure
08/26/2003US6610717 Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease
08/26/2003US6610715 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
08/26/2003US6610714 Non-nucleoside reverse transcriptase inhibitors
08/26/2003US6610713 Treating cell with cholinergic agonist
08/26/2003US6610709 2-n-substituted or unsubstituted-2-amino-5-methylpiperidine-3,4-diols and processes for the preparation thereof
08/26/2003US6610704 Antithrombotic amides
08/26/2003US6610700 Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example
08/26/2003US6610696 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides)
08/26/2003US6610695 Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease
08/26/2003US6610692 Anticoagulants
08/26/2003US6610690 Administering optically pure (S,S) enantiomer of reboxetine
08/26/2003US6610689 Viricides
08/26/2003US6610688 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
08/26/2003US6610687 Benzofuranylsulfonates
08/26/2003US6610685 Fused indole derivatives
08/26/2003US6610684 Fused azepinone cyclin dependent kinase inhibitors
08/26/2003US6610683 Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
08/26/2003US6610682 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier
08/26/2003US6610681 Neurotherapeutic clavulanate composition and method
08/26/2003US6610680 Non-peptidyl vasopressin V1A antagonists
08/26/2003US6610678 Corticotropin-releasing factor antagonists; treating endocrine, psychiatric or neurologic disorders
1 ... 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 ... 1564